Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic. At the core of the partnership are two candidates in the early preclinical assessment stage, both discovered using Marengo’s proprietary Selective T Cell Activation Repertoire (STAR) antibody fusion platform. Source: Biospace 1/8/2022